Skip to main
HOLX
HOLX logo

Hologic (HOLX) Stock Forecast & Price Target

Hologic (HOLX) Analyst Ratings

Based on 32 analyst ratings
Buy
Strong Buy 19%
Buy 25%
Hold 53%
Sell 3%
Strong Sell 0%

Bulls say

Hologic's stock outlook is positively influenced by expected high-single digit growth in its Molecular Diagnostics segment, supported by an increased utilization of its Panther systems, which have more than 3,300 units installed globally. The company anticipates a 4% compound annual growth rate (CAGR) in revenue from calendar year 2024 to 2026, driven by organic growth in procedure volumes, new product launches, and strategic acquisitions, alongside projected annual margin expansion of approximately 30 basis points. Additionally, a bull case scenario indicates potential revenue growth could accelerate to the high-single digits, underpinned by robust performance in Diagnostics and Breast Health, leading to improved operating margins and earnings significantly surpassing consensus estimates.

Bears say

Hologic's management has recently revised its long-term revenue growth targets downward from 5-7% to a more modest mid-single-digit growth estimate, reflecting broader concerns about the company's revenue trajectory, particularly in the Diagnostics and Breast Health segments. The company's projections for constant currency revenue growth have been adjusted to between 1.3% and 2.5%, significantly lower than previous forecasts, and organic revenue growth has also seen a decrease, indicating potential ongoing challenges in meeting growth expectations. Additionally, a notable decline in Breast Health sales by 5.8% and concerns about customer purchasing delays further underpin the negative outlook for Hologic's financial performance in fiscal years 2025 and 2026.

Hologic (HOLX) has been analyzed by 32 analysts, with a consensus rating of Buy. 19% of analysts recommend a Strong Buy, 25% recommend Buy, 53% suggest Holding, 3% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hologic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hologic (HOLX) Forecast

Analysts have given Hologic (HOLX) a Buy based on their latest research and market trends.

According to 32 analysts, Hologic (HOLX) has a Buy consensus rating as of Jul 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $60.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $60.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hologic (HOLX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.